These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24561132)

  • 21. New technologies provide insights into genetic basis of psychiatric disorders and explain their co-morbidity.
    Rudan I
    Psychiatr Danub; 2010 Jun; 22(2):190-2. PubMed ID: 20562745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacologic implications of neurobiological models of schizophrenia.
    Goff DC
    Harv Rev Psychiatry; 2005; 13(6):352-9. PubMed ID: 16373329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The emerging spectrum of allelic variation in schizophrenia: current evidence and strategies for the identification and functional characterization of common and rare variants.
    Mowry BJ; Gratten J
    Mol Psychiatry; 2013 Jan; 18(1):38-52. PubMed ID: 22547114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Schizophrenia: diverse approaches to a complex disease.
    Sawa A; Snyder SH
    Science; 2002 Apr; 296(5568):692-5. PubMed ID: 11976442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment.
    Millan MJ; Fone K; Steckler T; Horan WP
    Eur Neuropsychopharmacol; 2014 May; 24(5):645-92. PubMed ID: 24820238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans.
    Neill JC; Harte MK; Haddad PM; Lydall ES; Dwyer DM
    Eur Neuropsychopharmacol; 2014 May; 24(5):822-35. PubMed ID: 24287012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developing therapeutics for schizophrenia and other psychotic disorders.
    Marek G; Merchant K
    NeuroRx; 2005 Oct; 2(4):579-89. PubMed ID: 16489367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Receptor polymorphism and response to treatment in schizophrenia].
    Szekeres G; Janka Z
    Orv Hetil; 2002 Sep; 143(35):2027-33. PubMed ID: 12387196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The genetic architecture of schizophrenia: new mutations and emerging paradigms.
    Rodriguez-Murillo L; Gogos JA; Karayiorgou M
    Annu Rev Med; 2012; 63():63-80. PubMed ID: 22034867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel Approaches for Identifying the Molecular Background of Schizophrenia.
    Golov AK; Kondratyev NV; Kostyuk GP; Golimbet AVE
    Cells; 2020 Jan; 9(1):. PubMed ID: 31963710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action.
    Wong EH; Tarazi FI; Shahid M
    Pharmacol Ther; 2010 May; 126(2):173-85. PubMed ID: 20171983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer Drug Development: New Targets for Cancer Treatment.
    Curt GA
    Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Messing up with traffic: different effects of antipsychotic agents on glutamate receptor complexes in vivo.
    Del'guidice T; Beaulieu JM
    Mol Pharmacol; 2008 May; 73(5):1339-42. PubMed ID: 18314495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenomics of antipsychotics efficacy for schizophrenia.
    Cacabelos R; Hashimoto R; Takeda M
    Psychiatry Clin Neurosci; 2011 Feb; 65(1):3-19. PubMed ID: 21265934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serotonergic approaches in the development of novel antipsychotics.
    Jones CA; McCreary AC
    Neuropharmacology; 2008 Nov; 55(6):1056-65. PubMed ID: 18621404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
    Arranz MJ; de Leon J
    Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic mouse models of schizophrenia: from hypothesis-based to susceptibility gene-based models.
    Chen J; Lipska BK; Weinberger DR
    Biol Psychiatry; 2006 Jun; 59(12):1180-8. PubMed ID: 16631133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrating genetic, functional genomic, and bioinformatics data in a systems biology approach to complex diseases: application to schizophrenia.
    Middleton FA; Rosenow C; Vailaya A; Kuchinsky A; Pato MT; Pato CN
    Methods Mol Biol; 2007; 401():337-64. PubMed ID: 18368374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glutamatergic mechanisms in schizophrenia.
    Tsai G; Coyle JT
    Annu Rev Pharmacol Toxicol; 2002; 42():165-79. PubMed ID: 11807169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.